AR activity in prostate cancer cells has been shown to activate the MAPK pathway as well as Src and to increase levels of cyclin D1 via a PI3K/mTOR-mediated mechanism [41,42,43,44,45]. This evidence concerns the gene CCND1 and prostate carcinoma.